Obesity
Conditions
Keywords
Exercise therapy, Physical fitness, Gaming, Child, Healthy lifestyle, Fitness testing
Brief summary
The primary purpose of this study is to examine the effects of regular exergaming for 8 weeks in 24 overweight/obese children and adolescents (10-17 years) on maximal aerobic fitness (VO2max) and physical activity levels measured before and after (8 weeks) intervention period, and in addition at follow-up (12 weeks). We also wish to investigate the effects on markers of cardio metabolic health and body composition, measured at baseline, 8 weeks and 12 weeks follow-up. Also, the participants gaming frequency will be registered throughout the 8 week period, as well as during the follow-up between 8 and 12 weeks. Aim of this study is to investigate if access to this game can provide health benefits for overweight/obese children and adolescents.
Interventions
BEHAVIORALExergaming
The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
Sponsors
Norwegian University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 24 Years
Healthy volunteers
No
Inclusion criteria
* Defined as overweight/obese for age and sex * Able to ride a bike for up to 60 minutes
Exclusion criteria
* Known cardiovascular disease * Taking beta-blockers or anti-arrhythmic drugs * Other diseases that restrict them from doing High-Intensity Training
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Daily time physical activity (moderate, vigorous and very vigorous) | 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period and at 12 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Daily average number of steps | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Daily time in sedentary activity (< 3.0 metabolic equivalents = METs) | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Daily time in moderate intensity activity (3.0-6.0 metabolic equivalents = METs) | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Daily time in vigorous intensity activity | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Daily time in very vigorous intensity activity (>9.0 metabolic equivalents = METs) | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Daily average total physical activity duration | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Bioelectrical impedance | 8 and 12 weeks | Body composition assessed using bioelectrical impedance analysis (InBody 720) |
| Daily average energy expenditure | 8 and 12 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 8 weeks and 12 weeks. |
| Fasting circulating glucose, as blood marker of cardiometabolic health | 8 and 12 weeks | — |
| Fasting triglycerides, LDL-, HDL- and Total cholesterol, as blood marker of cardiometabolic health | 8 and 12 weeks | — |
| Circulating insulin concentration, as blood marker of cardiometabolic health | 8 and 12 weeks | — |
| glucose response to a 2 hour glucose tolerance test, as blood marker of cardiometabolic health | 8 and 12 weeks | — |
| VO2max | 8 and 12 weeks | Maximal Aerobic Capacity |
| Daily time physical activity (moderate, vigorous and very vigorous) | 8 weeks | Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period and at 8 weeks |
| Blood Pressure | 8 and 12 weeks | — |
Countries
Norway
Outcome results
None listed